AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) [clinicaltrials:NCT02238353]

Bio2RDF uri

AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) [clinicaltrials:NCT02238353]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02238353

Bio2RDF identifier

NCT02238353

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02238353

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

Comparative analysis of ...... nasal corticosteroids.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

AZELASTINE/FLUTICASONE (AZE/FL ...... ness in Allergic Rhinitis (AR)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:other outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:other-outcome]

change in expression of inflammatory mediators (Histamine / Substance P / IL-5 / EPO) 4 weeks after treatment [clinicaltrials_resource:3e98672ee4588d6971a71b04970ddec9]

change in expression of inflammatory mediators (Histamine / Substance P / IL-5 / EPO) 4 weeks after treatment [clinicaltrials_resource:673e75cac3257d10ff236bd138f76984]

change in expression of inflammatory mediators (Histamine / Substance P / IL-5 / EPO) 4 weeks after treatment [clinicaltrials_resource:832718e1d1de25d140644ba53074f391]

change in expression of inflammatory mediators (Histamine / Substance P / IL-5 / EPO) 4 weeks after treatment [clinicaltrials_resource:fe7cdf0214cafb6c6ffeb55ad19d449c]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

change in expression of inflammatory mediators (Histamine / Substance P / IL-5 / EPO) 4 weeks after treatment [clinicaltrials_resource:9e99caadabf8959435471b4e89e912e6]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

change in expression of inflammatory mediators (Histamine / Substance P / IL-5 / EPO) 4 weeks after treatment [clinicaltrials_resource:603edff5424e7f00fe9d307b28eb99c6]

completion date [clinicaltrials_vocabulary:completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Allergic Rhinitis [clinicaltrials_resource:39813c7b2fe02632613877e350a74e0d]

House Dust Mite Allergy [clinicaltrials_resource:ff4c19e2bcf8f2f479d0409017092556]

condition browse [clinicaltrials_vocabulary:condition-browse]

Rhinitis [clinicaltrials_resource:fd63913fd6274dc8c62d0042ccf44b75]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Rhinitis [clinicaltrials_resource:fd63913fd6274dc8c62d0042ccf44b75]

country [clinicaltrials_vocabulary:country]

Belgium [clinicaltrials_resource:6c1674d14bf5f95742f572cddb0641a7]

detailed description [clinicaltrials_vocabulary:detailed-description]

Comparative analysis of ...... nasal corticosteroids.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02238353 [clinicaltrials_resource:9bf8b896604d8028ca1e0b85fbc1bfbb]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo [clinicaltrials_resource:1a394d2a1ae4f1578093d026b4454e9b]

azelastine + fluticasone [clinicaltrials_resource:31558dabca9ed414c23fe3a1aef0361f]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Azelastine [clinicaltrials_resource:8392c23440ff4ab479a3273f1fd10de1]

Fluticasone [clinicaltrials_resource:e3b5d5116005c5baf90b256b2fe0af83]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Universitaire Ziekenhuizen Leuven [clinicaltrials_resource:aeebf36ef197b4467bc8553fcfb4da2a]

location [clinicaltrials_vocabulary:location]

Uz Leuven Dienst Nko [clinicaltrials_resource:b38b56d5b837d7315396289fb1a95fd4]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02238353

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

AZE/FLU Nasal Spray on Symptom ...... ness in Allergic Rhinitis (AR)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

azelastine/fluticasone AZE/FLU

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

peter hellings, MD [clinicaltrials_resource:18248376eeb19c024cb4da9c725477e3]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

Belgium: Ethics Committee [clinicaltrials_resource:e9d76176e0b96a1ccc9ceda4c66a8079]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Universitaire Ziekenhuizen Leuven [clinicaltrials_resource:aeebf36ef197b4467bc8553fcfb4da2a]

start date [clinicaltrials_vocabulary:start-date]

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02238353 study design [clinicaltrials_resource:c8cb941df9e260ea5991edfa7e3a52df]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02238353

verification date [clinicaltrials_vocabulary:verification-date]

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02238353

http://www.w3.org/2001/XMLSchema#string

title

AZELASTINE/FLUTICASONE (AZE/FL ...... ness in Allergic Rhinitis (AR)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

AZELASTINE/FLUTICASONE (AZE/FL ...... ) [clinicaltrials:NCT02238353]

@en